Here are the S-1 registration statements from Freenome, Inc. (FRNM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow FRNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FRNM filings page.
Freenome, Inc. (FRNM) has filed an S-1 to register up to 75,188,742 shares of common stock for resale by existing holders, including PIPE investors, the SPAC sponsor and initial shareholders, former Freenome Holdings equity holders, option and RSU holders, Roche (via a convertible note conversion) and a private warrant holder. Freenome will not receive proceeds from these secondary sales.
The company may receive up to $36.3 million if all registered options and the private warrant are exercised for cash; shares outstanding were 107,446,814 at the Business Combination closing and would be 112,549,251 assuming full exercise. Freenome is an early cancer detection company focused on blood-based, multiomics tests powered by AI/ML, initially centered on colorectal cancer (CRC). Its SimpleScreen CRC blood test has FDA approval for average‑risk adults 45+, is supported by the PREEMPT CRC study, and will be commercialized in the U.S. by Abbott under an exclusive agreement.
Freenome reports large, ongoing losses as it scales: net losses of $132.6 million for the six months ended June 30 2026, and $219.3 million and $274.4 million for 2025 and 2024, with an accumulated deficit of $1.5 billion. Management believes existing cash, including Business Combination and PIPE proceeds, will fund operations into 2028 but highlights potential future capital needs. The company is an emerging growth company and smaller reporting company, allowing reduced disclosure and delayed adoption of new accounting standards.